ArticleBMC infectious diseases2025
Emergence of ST11-KL64 carbapenem-resistant hypervirulent Klebsiella Pneumoniae isolates harboring bla
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Definitional ambiguity and the dual threat of Hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis.Infection · 2026Pooled it
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Emergence of carbapenem-resistant putative hypervirulentEmerging microbes & infections · 2026Article
- Genomic characterization of CTX-M-15-producing Klebsiella pneumoniae ST709-KL9 from neonatal bacteraemia in eastern India.Molecular biology reports · 2026Article
- Article
- Berberine inhibits the AcrB efflux pump and synergizes with meropenem against carbapenem-resistant hypervirulent Klebsiella pneumoniae: mechanistic insights and in vivo validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Genomic characterization of carbapenemase-producing Enterobacterales from wastewater reveals the convergence of KPC-2 and GES-16 in Brazil.Environmental monitoring and assessment · 2026Article
- A dual-tier plasmid network model underpins the evolutionary success of pandemic Klebsiella pneumoniae ST11.Scientific reports · 2026Article
- Emerging hypervirulent and extensively drug-resistant Klebsiella pneumoniae with potent biofilm formation as a new clinical challenge.Molecular biology reports · 2026Article
- Epidemiology, Virulence Factors, and Antibacterial Resistance ofMedicina (Kaunas, Lithuania) · 2026Review
- Isolation, characterization, and therapeutic assessment of novel phage vB_LSKP32 targeting KL64-type carbapenem-resistant Klebsiella pneumoniae.Archives of virology · 2026Article
- Phenotypic and genomic characterization of tigecycline heteroresistance in carbapenem-resistantMicrobiology spectrum · 2026Article
- Epidemiological and functional insights intoMicrobiology spectrum · 2026Article
- Epidemiological and genomic profiles of NDM-1-Producing ST25-KL2 carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Hangzhou, China.BMC microbiology · 2026Article
- Antimicrobial Resistance, Molecular Epidemiology, and Virulence Profiles of Hypervirulent Carbapenem-ResistantInfection and drug resistance · 2026Article
- Genetic characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Genomic and functional characterization of ST11-KL64 hypervirulence-associated carbapenem-resistantFrontiers in microbiology · 2026Article
- Development and Validation of a Nomogram for Predicting Mortality in Patients with Multidrug-Resistant Bacteria Infection: A Retrospective Cohort Study in China.International journal of general medicine · 2026Article
- Phenotypic characteristics and plasmid structure differences between ST11 carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-HvKP) poses a critical global health threat. However, molecular epidemiological data on CR-HvKP in Western China remain scarce. This study aimed to characterize the clinical profiles, molecular features, and risk factors of CR-HvKP isolates in Western China.
methodsSixty-eight carbapenem-resistant Klebsiella pneumoniae (CRKP) clinical isolates were collected from January to December in 2024. Clinical characterization included antimicrobial susceptibility profiling and hypermucoviscosity assessment via string test. Detection of carbapenemases using inhibitor enhancement test. Molecular characteristics of CRKP included serotype, carbapenemases, virulence-associated factors, and multilocus sequence typing (MLST) performed by using the PCR method. CR-HvKP was defined as the presence of any one of rmpA, rmpA2, iroB, iucA, and peg-344. Risk factors were initially evaluated using univariate logistic regression analysis, with significant variables subsequently incorporated into a multivariate regression model. A p-value < 0.05 was considered statistically significant.
resultsAmong 68 CRKP isolates, 36 were identified as CR-HvKP, all harboring the iucA gene (100%, 36/36). However, only 22.2% (8/36) of string test results correlated with virulence gene presence. All CRKP strains exhibited high resistance to most antibiotics, with comparatively lower resistance rates observed for tigecycline (0%) and polymyxin B (14.7%). Carbapenemase production was the predominant resistance mechanism, with 61.8% (42/68) carrying bla
conclusionsThe ST11-KL64 CR-HvKP clone harboring bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.